Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2

Kevin Barley, Larysa Sanchez, Hearn J. Cho, Samir Parekh, Deepu Madduri, Joshua Richter, Luis Isola, Talia Goldstein, Amishi Dhadwal, Katarzyna Zarychta, Gillian Morgan Sanchez, Donna Catamero, Daniel Verina, Erika Florendo, Moon hee Yum, Lisa La, Jude Gullie, Elaine Chan, Sundar Jagannath, Ajai Chari

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)E51-E54
JournalAmerican Journal of Hematology
Issue number2
StatePublished - 1 Feb 2020

Cite this